Stocktoria

Damora Therapeutics, Inc. DMRA

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-29

Damora Therapeutics, Inc. statistics & valuation

Market cap$1.6B
P / B6.5×
Return on equity-87.3%
Return on capital-87.7%
Graham number +274.5%$116.09

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($116.09); a green figure means the price is below it.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
2019202020212022202320242025
Return on equity (%)
-21.10% -44.10% -99.80% -118.60% -135.40% -87.30% 2019202020212022202320242025
Shares outstanding
259966 25.3M 25.3M 25.7M 1.1M 1.3M 1.6M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-64.50% -20.30% -42.30% -84.20% -100.30% -125.10% -80.50% 2019202020212022202320242025
Free cash flow margin (%)
2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.05 -$2.43 -$36.08 -$18.53 $3.98 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on assets-80.5%-125.1%-100.3%-84.2%-42.3%-20.3%-64.5%
Return on equity-87.3%-135.4%-118.6%-99.8%-44.1%-21.1%51.3%
Current ratio12.9814.076.315.7524.2330.427.07

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.